Revisto Secures $4M in Seed Funding to Transform Pharmaceutical Marketing Material Review
Revisto is revolutionizing the MLR review process, a traditionally cumbersome task hindered by multiple stakeholders and stringent regulations.
Company Name: Revisto
Location: Austin, TX
Industry: AI-Powered Solutions for Life Sciences
Funding Details:
Revisto raised $4M in Seed funding, led by LiveOak Ventures, with participation from Eli Lilly and Company, Tau Ventures, and Arkin Digital Health.
Purpose of Investment:
The funding will be used to accelerate growth, drive innovation, and expand services to address the evolving needs of the life sciences industry.
Leadership:
Revisto is led by CEO Ferry Tamtoro, who is focused on streamlining marketing operations and ensuring compliance for pharmaceutical companies.
Product:
Revisto provides an AI-powered solution to streamline the medical, legal, and regulatory (MLR) review process for pharmaceutical marketing materials. Key features include:
- Brand-Specific AI Integration: Tailored to customers’ unique brand data.
- Regulatory Compliance: Real-time adherence to FDA 21 CFR regulations and guidelines.
- Workflow Optimization: Seamless integration with tools like Veeva Vault PromoMats to simplify complex review workflows.
- Efficiency Gains: Reducing costs, manual processes, and compliance risks while improving operational efficiency.
About the Company:
Revisto is revolutionizing the MLR review process, a traditionally cumbersome task hindered by multiple stakeholders and stringent regulations. By leveraging advanced AI, the platform empowers pharmaceutical companies to streamline their marketing operations and mitigate compliance risks, ensuring faster and more effective reviews.
